enGene’s Detalimogene On Track For H2 2026 FDA Filing In NMIBC

 
• By Alaric DeArment
  
enGene announced positive Phase II data from the LEGEND study of detalimogene voraplasmid in NMIBC. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies